Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Sagittarius

Financiado

A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TRE...

A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIAL SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC). Approximately half of all LRCC patients relapse within two years from time of curative surgery because of imagin... ver más

30/06/2028

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 9 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-27

HORIZON-MISS-2022-CANCER-01-03: Pragmatic clinical trials to optimi... ExpectedOutcome:While cancer research and innovation have generated novel treatment options, cancer...

I+D

Cerrada hace 2 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

2.80M€ | Lider

IMIM

902.45K€ | Participante

FUNDACIO PRIVADA INSTITUT D'...

590.01K€ | Participante

SPOREDATA OU

400.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RYC-2013-14097 Advanced human cancer: Therapies guided by mutational signat... 309K€ Cerrado

IJC2020-044728-I Finding the drivers of cancer and contribute to precision me... 31K€ Cerrado

PID2019-106247GB-I00 HETEROGENEIDAD GENOMICA DE LAS CELULAS TUMORALES CIRCULANTES 363K€ Cerrado

PID2019-111356RA-I00 TERAPIAS DIRIGIDAS CONTRA LA INESTABILIDAD CROMOSOMICA EN CA... 169K€ Cerrado

PDC2022-133056-I00 TRADUCIENDO LA BIOLOGIA TUMORAL EN MEDICINA PERSONALIZADA: D... 133K€ Cerrado

CPP2021-009037 DESARROLLO DE TEST DIAGNÓSTICOS BASADOS EN DNA PARA PERSONAL... 474K€ Cerrado

Duración del proyecto: 62 meses Fecha Inicio: 2023-04-27
Fecha Fin: 2028-06-30

Líder del proyecto

IFOMISTITUTO FONDAZIONE DI ONCOLOGIA MOLECOLA... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto SAGITTARIUS aim to optimize the clinical management of locoregional stage II high-risk/stage III colon cancer (LRCC). Approximately half of all LRCC patients relapse within two years from time of curative surgery because of imaging-undetectable micro-metastatic residual disease (MMRD). Given the lack of reliable predictors of individual risk, LRCC patients are treated with a one-fits-all adjuvant chemotherapy. This gunshot approach results in either over- or under-treatment. Measuring circulating tumor DNA (ctDNA) in the patients’ bloodstream can diagnose MMRD. Retrospective studies show that ctDNA detection after surgery predicts cancer recurrence with high sensitivity and specificity. SAGITTARIUS will deploy a ctDNA assay to detect the absence, presence, or persistence of MMRD in individual patients. The diagnosis of MMRD will guide and personalize therapeutic interventions. SAGITTARIUS is a pragmatic trial whereby real-world patients are treated in two parallel trials based on their MMRD status and the genomic landscape of their tumors. ctDNA positive patients are randomized to conventional or personalized targeted therapy. ctDNA negative patients are randomized to a physician-driven therapy or a Wait&See strategy. The efficacy and effectiveness of this potentially ground-breaking new strategy of care will be measured via multiple outcomes, including safety and time to events variables, patient-reported outcome measures, and health-economics evaluation. Since colon cancer deaths are usually associated with metastases rather than local disease, MMRD will also reclassify how this disease is perceived by clinicians. This new prism will allow for treatment to be better matched against the tumor biology, also allowing for better monitoring – via ctDNA – to assess disease evolution in each patient, minimizing harm and maximizing the odds of cure. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores